Abstract Book of ESMO Breast Cancer 2024, Berlin, Germany, 15-17 May 2024Publication of this Abstract book is supported by the European Society for Medical Oncology May 2024 Previous vol/issue Next vol/issue Actions for selected articles
Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. No forward-lo...
Only abstracts for whichno conclusive data are available at the time of the abstract submission deadline of9 January 2024will be considered for late-breaking status. The workmust nothave been previously published in any publication in a peer review setting or presented at a meeting of any other ...
Abstract Book of the Molecular Analysis for Precision Oncology Congress (MAP) 2024 London, UK, 16-18 October 2024Publication of this Abstract book is supported by the European Society for Medical Oncology October 2024 Previous vol/issue Next vol/issue ...
Presented at: 2024 European Society for Medical Oncology Congress; September 13-17, 2024; Barcelona, Spain. Abstract LBA13. FDA approves Novartis Kisqali to reduce risk of recurrence in people with HR+/HER2- early breast cancer. News release. Novartis Pharmaceuticals Corporation. September 17, ...
◆ 下次会议:2024年欧洲肿瘤内科学会ESMO妇科肿瘤大会 ◆ 会议简介: 2023欧洲肿瘤内科学会(ESMO)妇科肿瘤学大会将2023年2月23日至24日在西班牙巴塞罗那以线上线下结合形式举行。首届会议将重点关注卵巢癌,会议将提供最新的见解并探索关键领域的未来发展:新诊断卵巢癌的治疗、晚期卵巢癌的一线维持治疗、复发性卵巢癌的...
The abstract submitted to ESMO was based on a data cut-off as ofApril 12, 2024; updated data based on a cut-off date ofJuly 9, 2024, are included below and are reported in the Company’s poster presentation at ESMO. The TAMARACK trial enrolled a total of 181 participan...
Abstract:150P Title:Phase 1/2a trial of CD200R1 inhibitor 23ME-00610; exploratory analyses of tissue-based and genetic biomarkers Session Type:Poster Session – Biomarkers and Translational Research (agnostic) Date and Time:September 15, 9:00-17:00 Central European Summer...
Abstract Presentation ENHERTU (trastuzumab deruxtecan/T-DXd; HER2 directed ADC) Lung Trastuzumab deruxtecan in patients with HER2 mutated metastatic non-small cell lung cancer: interim results from the phase 2 DESTINY-Lung02 trial Y. Goto ...
The abstract is published in the ESMO Congress 2023 Abstract Book, a supplement to the official ESMO journal, Annals of Oncology. The poster is available at the Annals of Oncology website and https://inspirna.com/presentations-publications/...